Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ravulizumab study in adults with IgA nephropathy
MOH_2024-06-02_013453Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ravulizumab in IgA nephropathy (IgAN) (3 cohorts), sponsored by AstraZeneca. Primary endpoint: Primary endpoint not reported in registry entry. Started May 2024; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on MOH_2024-06-02_013453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-06-02_013453.